TheraCIM h-R3: Phase I/II

TheraCIM gave an objective response in 8 of 11 evaluable patients, with 7 complete responses, in a Canadian Phase I/II trial. Side effects were infrequent and mild, although 4 of 25 patients stopped treatment early. ...